<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30023">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01799317</url>
  </required_header>
  <id_info>
    <org_study_id>IBS-05</org_study_id>
    <secondary_id>R01DK035423-19</secondary_id>
    <nct_id>NCT01799317</nct_id>
  </id_info>
  <brief_title>How Bone is Made in Children Receiving Dialysis</brief_title>
  <official_title>Regulation of Bone Mineralization in Renal Osteodystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Hospital Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Loma Linda University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <authority>United States: National Institute of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study outlined is designed to measure and to determine whether the combined use of
      vitamin D2 (ergocalciferoI) and 1-alpha-hydroxyvitamin D2 (doxercalciferol)) or
      doxercalciferol alone  will correct the mineralization defect in pediatric patients with
      established secondary hyperparathyroidism (2°HPT) undergoing regular peritoneal dialysis.
      Serum phosphorus levels will be controlled with a calcium¬-free-metal free phosphate binder;
      (obtained at baseline and after 8 months of treatment)  sevelamer. Indices of bone
      mineralization obtained at baseline and after 8 months of treatment will be measured by
      quantitative histomorphometry in iliac crest bone biopsies after double tetracycline
      labeling. Immunohistochemistry will be done in specimens of bone biopsies from iliac crest
      to examine the expression for selected markers of bone turnover and mineralization such as
      FGF-23, DMP1, MEPE and OPG. Serum PTH levels will be measured with the 1st and 2nd
      generation immunometric assay (PTH-IMAs) and fibroblast growth factor-23 (FGF-23) will be
      determined by one assay with specific detection antibodies that are against epitopes within
      the C-terminus of FGF-23 and another assay that uses antibodies against epitopes within the
      N- and C-terminal portions of the molecule respectively. The value of non-invasive
      assessment of bone mass by quantitative computed tomography (QCT) and its relationship with
      vascular disease determined by ultrasound (US) of intimal carotid thickness (CIMT) will be
      correlated with bone histomorphometry and the different biochemical determinations.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Improvement of bone mineralization defect demonstrated by bone histomorphometry</measure>
    <time_frame>8 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Iliac crest bone biopsy pre and post treatment with vitamin D2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiographic improvement of skeletal abnormalities associated with renal osteodystrophy</measure>
    <time_frame>8 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will compare skeletal lesions identified through radiographic studies with bone histomorphometry pre and post treatment with vitamin D2</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Bone Mineralization Defect</condition>
  <arm_group>
    <arm_group_label>Treatment with vitamin D2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vitamin D2 50,000u titrated to serum 25(OH)D values given orally once a month in addition to standard of care: Doxercalciferol escalating doses beginning at 2.5 mcg given orally thrice weekly. Sevelamer Carbonate 800 mg (1600- 4800 mg) given orally with each meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of Care: Doxercalciferol escalating doses beginning at 2.5 mcg given orally thrice weekly. Sevelamer Carbonate 800 mg (1600- 4800 mg) given orally with each meal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D2</intervention_name>
    <description>These patients will receive standard of care vitamin D 1,25 therapy with intervention of vitamin D2</description>
    <arm_group_label>Treatment with vitamin D2</arm_group_label>
    <other_name>Ergocalciferol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  medically stable patients

          -  6-21 years old

          -  undergoing treatment with continuous cycling peritoneal dialysis

          -  evidence of mineralization defect and secondary hyperparathyroidism

        Exclusion Criteria:

          -  histopathological lesion of bone such as adynamic bone or osteomalacia

          -  poor compliance

          -  current treatment with prednisone or other immunosuppressives

          -  treatment with human recombinant growth hormone

          -  parathyroidectomy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isidro Salusky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Isidro Salusky, MD</last_name>
    <phone>310.206.6987</phone>
    <email>isalusky@mednet.ucla.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Loma Linda University</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shobbha Sahney, MD</last_name>
      <phone>909-558-8242</phone>
      <email>ssahney@llu.edu</email>
    </contact>
    <investigator>
      <last_name>Shobha Sahney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Lemley, MD</last_name>
      <phone>323-361-2295</phone>
      <email>klemley@chla.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Kevin Lemley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 22, 2013</lastchanged_date>
  <firstreceived_date>February 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Isidro Salusky, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Renal Osteodystrophy</mesh_term>
    <mesh_term>Calcinosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
